432001-30-4 Usage
Uses
Used in Pharmaceutical and Agrochemical Synthesis:
EAPAA is utilized as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, capitalizing on its structural properties to create a diverse range of compounds with potential therapeutic and pesticidal applications.
Used in Medicinal Chemistry Research:
As a compound with demonstrated antitumor activity, EAPAA is employed in medicinal chemistry research to explore its potential in the development of novel anti-cancer agents. Its structure may offer insights into the design of new drugs targeting cancer cells.
Used in Enzyme Inhibition:
EAPAA has been identified as a potential inhibitor of the enzyme carbonic anhydrase. This characteristic positions it as a candidate for the development of new therapies for conditions such as glaucoma and epilepsy, where carbonic anhydrase inhibition can be beneficial.
Used in Drug Design:
The unique structure of EAPAA, including its sulfonamide functional group and ethoxy-benzenesulfonyl substituent, makes it a valuable compound in drug design. Its properties can be leveraged to create new drugs with specific targeting capabilities, potentially leading to more effective treatments for various diseases and conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 432001-30-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,3,2,0,0 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 432001-30:
(8*4)+(7*3)+(6*2)+(5*0)+(4*0)+(3*1)+(2*3)+(1*0)=74
74 % 10 = 4
So 432001-30-4 is a valid CAS Registry Number.
432001-30-4Relevant academic research and scientific papers
Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists
Quattropani, Anna,Dorbais, Jér?me,Covini, David,Pittet, Pierre-André,Colovray, Véronique,Thomas, Russell J.,Coxhead, Richard,Halazy, Serge,Scheer, Alexander,Missotten, Marc,Ayala, Guidon,Bradshaw, Charles,De Raemy-Schenk, Anne-Marie,Nichols, Anthony,Cirillo, Rocco,Tos, Enrico Gillio,Giachetti, Claudio,Golzio, Lucia,Marinelli, Paolo,Church, Dennis J.,Barberis, Claude,Chollet, André,Schwarz, Matthias K.
, p. 7882 - 7905 (2007/10/03)
We report a novel chemical class of potent oxytocin receptor antagonists showing a high degree of selectivity against the closely related vasopressin receptors (Via, V1b, V2). An initial compound, 7, was shown to be active in an animal model of preterm labor when administered by the intravenous but not by the oral route. Stepwise SAR investigations around the different structural elements revealed one position, the arenesulfonyl moiety, to be amenable to structural changes. Consequently, this position was used to introduce a variety of substituents to improve the physicochemical properties. Some of the resulting analogues were found to be superior to 7 both in terms of potency in vitro and aqueous solubility, which translated into significantly improved efficacy in the animal model after intravenous and oral administration. The best compound, 73, potently inhibited oxytocin-induced uterine contractions in nonpregnant rats and reduced spontaneous uterine contractions in late-term pregnant rats.
